Zusammenfassung
Phase I clinical trials are essential to bringing novel therapies from chemical development to widespread use. Traditional approaches to dose-finding in Phase I trials, such as the ‘3 + 3’ method and the continual reassessment method (CRM), provide a principled approach for escalating across dose levels. However, these methods lack the ability to incorporate uncertainty regarding the ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric